期刊文献+

耐氟康唑光滑念珠菌ERG11基因突变分析 被引量:4

Analysis of ERG11 gene mutations in fluconazole-resistant Candida glabrata strains
原文传递
导出
摘要 目的 分析耐药氟康唑光滑念珠菌ERG11基因突变情况,探讨ERG11基因突变在光滑念珠菌耐药性形成中的作用.方法 分别将氟康唑耐药光滑念珠菌株9株和敏感株10株的ERG11基因克隆至pUC57-T载体,利用载体上的通用引物对其ERG11基因整个开放读码框进行双向测序,将测序结果与网上公布的标准序列进行比对.结果 19株光滑念珠菌耐药株和敏感株ERG11基因共存在10个点突变,均为同义突变,无错义突变和移码突变.其中5个点突变在耐药株和敏感株中均出现,3个只出现在耐药株,2个只出现在敏感株.点突变主要位于ERG11基因1320~2200 bp,出现频率最高的3个点突变为T2117A、A1583G、T1328C.结论 光滑念珠菌ERG11基因序列存在多态性,未发现因ERG11基因突变引起靶酶氨基酸改变而导致的光滑念珠菌对氟康唑耐药. Objective To study the mutations of ERG11 gene which encodes P450 lanosterol 14-α demethylase, and to explore the possible role of ERG11 gene in inducing fluconazole resistance in Candida glabrata. Methods ERG11 genes of 9 fluconazole-resistant Candida glabrata isolates and 10 fluconazole-sensitive Candida glabrata isolates were cloned into pUC57-T vector. The open reading frame of ERG11 gene were sequenced by two directional sequencing using universal primers. All sequences were compared with the published sequence. Results Ten kinds of synonymous point mutation were found. Neither missense mutation nor frame-shifting mutation was found. Among the 10 kinds of synonymous point mutation, 5 were found in both fluconazole-resistant and fluconazolesensitive Candida glabrata isolates, and 3 were only found in fluconazole-resistant isolates, 2 were only found in fluconazole-sensitive ones. The majority of the point mutations were located between 1320-2200 base pair of ERG11 gene. Conclusions There are ERG11 gene polymorphisms in clinical strains of Candida glabrata. ERG11 gene mutations are not found to be involved in the development of fluconazole resistance in Candida glabrata.
出处 《中华传染病杂志》 CAS CSCD 北大核心 2010年第6期331-335,共5页 Chinese Journal of Infectious Diseases
基金 上海市卫生局青年科研项目(2008Y030) “艾滋病和病毒性肝炎等重大传染病防治”科技重大专项(2009ZX10003-017)
关键词 念珠菌 光滑 氟康唑 抗药性 细菌 ERG11基因 真菌 突变 遗传密码 Candida glabrata Fluconazole Drug resistance, bacterial ERG11 genes,fungal Mutation Genetic code
  • 相关文献

参考文献10

  • 1Pfaller MA,Diekema DJ.Twelve years of fluconazole in clinical practice.global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.Clin Microbiol Infect,2004,10 Suppl 1:S11-23.
  • 2Pfaller MA,Pappas PG,Wingard JR.Invasive fungal pathogens:current epidemiological trends.Clin Infect Dis,2006,43 Suppl 1:S3-14.
  • 3Perea S,Patterson TF.Antifungal resistance in pathogenic fungi.Clin Infect Dis,2002,35:1073-1080.
  • 4White TC.Increased mRNA levels of ERG16,CDR,and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus.Antimicrob Agents Chemother,1997,41:1482-1487.
  • 5Sanguinetti M,Posteraro B,Fiori B,et al.Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.Antimicrob Agents Chemother,2005,49:668-679.
  • 6Posteraro B,Tumbarello M,La Sorda M,et al.Azole resistance of Candida glabrata in a case of recurrent fungemia.J Clin Microbiol,2006,44:3046-3047.
  • 7Joseph-Horne T,Hollomon DW.Molecular mechanisms of azole resistance in fungi.FEMS Microbiol Lett,1997,149:141-149.
  • 8Redding SW,Kirkpatrick WR,Saville S,et al.Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation.J Clin Microbiol,2003,41:619-622.
  • 9Geber A,Hitchcock CA,Swartz JE,et al.Deletion of the Candida glabrata ERG3 and ERG11 genes:effect on cell viability,cell growth,sterol composition,and antifungal susceptibility.Antimicrob Agents Chemother,1995,39:2708-2717.
  • 10Brun S,Bergès T,Poupard P,et al.Mechanisms of azole resistance in petite mutants of Candida glabrata.Antimicrob Agents Chemother,2004,48:1788-1796.

同被引文献59

  • 1Martins HPR, Silva MLD, Paiva LCF, et al. Efficacy of Flucon- azole and Nystatin in the Treatment of Vaginal Candida Species [J]. Acta Derm Venereol, 2012,92 : 78-82.
  • 2Gygax SE, Vermitsky JP, Chadwick SG, et al. Antifungal Resist ance of Candida glabrata Vaginal Isolates and Development of a Quantitative Reverse Transeription-PCR-Based Azole Susceptibility Assay[J]. Antimierobial Agents and Chemotherapy, 2008,52(9):3424-3426.
  • 3Richter SS, Galask RP, Messer SA, et al. Antifungal Susceptibili- ties of Candida Species Causing Vulvovaginitis and Epidemiology of Recurrent Cases[J]. J Clin Microbiol,2005,43(5) :2155-2162.
  • 4Borst A, Raimer MT,Warnoek DW. Rapid acquisition of stable az- ole resistance by Candida glabrata isolates obtained before the clinical introduction of flueonazole[J]. Antimicmb Agents Che- mother,2005,49(2) :783-787.
  • 5Bennett JE,Izumikawa K, Marr KA. Mechanism of increased flu- conazole resistance in Candida glabrata during prophylaxis[J]. Antimierob Agents Chemother, 2004,48(5):1773-1777.
  • 6Posteraro B, Sanguinetti M, Fiori B, et al. Caspofungin activity a- gainst clinical isolates of azole cross resistant Candida glabrata overexpressing efflux pump genes[J]. J Antimierob Chemother, 2006,58(2) :458-461.
  • 7Wada S, Tanabe K, Yamazaki A, et al. Phosphorylation of Candidaglabrata ATP binding cassette transporter Cdrlp regulates drug efflux activity and ATPase stability[J]. J Biol Chem, 2005,280 (1) :94-103.
  • 8Vermitsky JP, Edlind TD. Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdrl Like transcription factor[J]. Antimicrob Agents Chemoth- er, 2004,48 (10):3773-3781.
  • 9Tsai HF, Krol AA, Sarti KE, et al. Candida glabrata PDRI, a transcriptional regulator of a pleiotropie drug resistance network, mediates azole resistance in clinical isolates and petite mutants [J]. Antimicrob Agents Chemother,2006,50(4) : 1384-1392.
  • 10Rogers PD, Vermitsky JP, Edlind TD, et al. Proteomic analysis of experimentally induced azole resistance in Candida glabrata[J]. J Antimicrob Chemother, 2006,58 (2) : 434-438.

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部